Market Access News | pharmaphorum

News

Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare kidney disease FSGS.

News

AstraZeneca's hyperkalaemia drug Lokelma could see its use by the NHS more than double thanks to updated guidance from NICE.

News

Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses.

News

Advances in therapeutics are outpacing the development of diagnostics due to policy and payment barriers, holding back effective, targeted care.

News

AbbVie has opened a new front in the pharma industry's efforts to reform the 340B drug discounting programme for safety net hospitals in the US.

News

A bid to limit access to the abortion pill mifepristone in the US, while the FDA carries out a review of the drug, has been blocked in the courts.